Nuclidium AG
Im Erasmushaus,
Bäumleingasse 18,
4051 Basel,
Switzerland
Nuclidium (DE) GmbH
Prinzregentenstr. 64,
81675 München,
Germany
NUCLIDIUM Presents Positive Phase I/II Results for First Copper-based PET Diagnostic in Neuroendocrine Tumors at EANM Congress 2025
NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States
NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
NUCLIDIUM Presents Positive Phase 1 Results of its Novel PET Imaging Agent 61-Cu-NuriPro™ at SNMMI 2025 Annual Meeting